RESPONSES TO R-CHOP CHEMOTHERAPY INCORPORATING BIOSIMILAR RITUXIMAB (TRUXIMA®) FOR THE FIRST LINE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA - INITIAL EXPERIENCE AT UNIVERSITY COLLEGE LONDON HOSPITAL: PF312